Showing results (3101-3110 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|May 22, 2016
Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast CancerBonny Parkinson, Rosalie Viney, Marion Haas, et al.
Pharmacoeconomics|May 23, 2016
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous UrticariaJonathan Graham, Doreen McBride, Donald Stull, et al.
Pharmacoeconomics|November 11, 2017
Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic ReviewPeter Ghijben, Yuanyuan Gu, Emily Lancsar, et al.
Pharmacoeconomics|December 10, 2017
Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalHema Mistry, Chidozie Nduka, Martin Connock, et al.
Pharmacoeconomics|November 29, 2017
Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular DiseaseUsha G Mallya, Susan H Boklage, Andrew Koren, et al.
Pharmacoeconomics|December 21, 2017
A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative ColitisEwa Stawowczyk, Paweł Kawalec
Pharmacoeconomics|October 21, 2017
International Regulations and Recommendations for Utility Data for Health Technology AssessmentDonna Rowen, Ismail Azzabi Zouraq, Helene Chevrou-Severac, et al.
Pharmacoeconomics|September 3, 2017
The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical AppraisalEmma McManus, Tracey Sach, Nick Levell
Pharmacoeconomics|September 16, 2017
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology AppraisalIrina A Tikhonova, Tracey Jones-Hughes, James Dunham, et al.
Pharmacoeconomics|September 22, 2017
Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalIñigo Bermejo, Matt Stevenson, Katy Cooper, et al.
Pageof 336